 The trial enrolls patients with moderate to severe Hidradenitis Suppurativa HS. The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints e.g., Hidradenitis Suppurativa Clinical Response HiSCR, Dermatology Life Quality Index DLQI, Visual Analog Scale VAS for disease, VAS for pain, Hidradenitis Suppurativa - Physicians Global Assessment HS-PGA, Modified Sartorius Score mSS. 